HMG- CoA reduktase hæmmere, der primært metaboliseres af CYP3A4 (f. eks. lovastation og simvastation), forventes at få en markant stigning af plasmakoncentrationen ved samtidig administration med Agenerase.
HMG-CoA reductase inhibitors which are highly dependent on CYP3A4 for metabolism, such as lovastatin and simvastatin, are expected to have markedly increased plasma concentrations when co-administered with Agenerase.